John A. Charlson, MD

Associate Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Medical Oncology

Languages

English

Cancer Center - Froedtert Hospital

(414) 805-6800

Education

MD - Doctor of Medicine

Biography

John Charlson, MD, is Associate Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in sarcoma, breast cancer and solid malignancies. He graduated from the University of Iowa, College of Medicine in 1999, and then completed an internal medicine residency at the Medical College of Wisconsin Affiliated hospitals, serving as chief resident. He completed his fellowship in oncology in 2007, and is board certified in medical oncology. Dr. Charlson is the MCW PI for several breast cancer and sarcoma clinical trials.

Research Interests

Dr. Charlson’s clinical focus is on the care of patients with sarcoma and breast cancer. Additionally, his time is spent on quality improvement efforts within the Cancer Center and as an investigator on a number of chemotherapy clinical trials. His research interests are health services research and outcomes of patients treated for breast cancer and sarcoma.

Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.

(D'Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, Carrasco Garcia I, Charlson JA, Choy E, Demetri GD, Druta M, Forcade E, Ganjoo KN, Glod J, Keedy VL, Le Cesne A, Liebner DA, Moreno V, Pollack SM, Schuetze SM, Schwartz GK, Strauss SJ, Tap WD, Thistlethwaite F, Valverde Morales CM, Wagner MJ, Wilky BA, McAlpine C, Hudson L, Navenot JM, Wang T, Bai J, Rafail S, Wang R, Sun A, Fernandes L, Van Winkle E, Elefant E, Lunt C, Norry E, Williams D, Biswas S, Van Tine BA.) Lancet. 2024 Apr 13;403(10435):1460-1471 PMID: 38554725 SCOPUS ID: 2-s2.0-85188995845 03/31/2024
Pre-Operative Radiotherapy in STS: Does Downsizing Matter?

(Gutkin PM, King DM, Charlson J, Wooldridge A, Hackbarth D, Kelly TR, Neilson J, Johnstone C, Bedi M.) Int J Radiat Oncol Biol Phys. 2023 Oct 01;117(2S):S148-S149 PMID: 37784375 10/03/2023
Radiomics Model for Predicting Pulmonary Metastasis in Sarcoma Patients.

(Prior PW Jr, Nasief HG, Mannem R, Charlson J, Fernando S, Bedi M.) Int J Radiat Oncol Biol Phys. 2023 Oct 01;117(2S):e708 PMID: 37786072 10/03/2023
Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma.

(Mittal S, Kadamberi IP, Chang H, Wang F, Kumar S, Tsaih SW, Walker CJ, Chaluvally-Raghavan P, Charlson J, Landesman Y, Pradeep S.) Exp Hematol Oncol. 2023 Sep 15;12(1):78 PMID: 37715291 PMCID: PMC10503035 SCOPUS ID: 2-s2.0-85171339411 09/16/2023
Medication self-management behaviors of adolescents and young adults with cancer.

(Erickson JM, Kamke-Jordan A, Lancaster IJ, Palou-Torres A, Esch M, Gonzalez A, Charlson J, Bingen K.) Support Care Cancer. 2023 Jun 10;31(7):390 PMID: 37300714 PMCID: PMC10256968 SCOPUS ID: 2-s2.0-85163126078 06/10/2023
The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma.

(Heater NK, Okuno S, Robinson S, Attia S, Seetharam M, Siontis BL, Yoon J, Chawla S, Milhem MM, Monga V, Skubitz K, Charlson J, Hirbe AC, Weiss MC, Van Tine B, Agulnik M.) J Clin Med. 2023 Mar 29;12(7) PMID: 37048645 PMCID: PMC10095464 04/14/2023
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.

(Gounder M, Ratan R, Alcindor T, Schöffski P, van der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, Attia S, Chawla S, D'Amato G, Federman N, Merriam P, Van Tine BA, Vincenzi B, Benson C, Bui NQ, Chugh R, Tinoco G, Charlson J, Dileo P, Hartner L, Lapeire L, Mazzeo F, Palmerini E, Reichardt P, Stacchiotti S, Bailey HH, Burgess MA, Cote GM, Davis LE, Deshpande H, Gelderblom H, Grignani G, Loggers E, Philip T, Pressey JG, Kummar S, Kasper B.) N Engl J Med. 2023 Mar 09;388(10):898-912 PMID: 36884323 03/09/2023
Stereotactic body radiotherapy for metastatic sarcoma to the lung: adding to the arsenal of local therapy.

(Gutkin PM, Gore E, Charlson J, Neilson JC, Johnstone C, King DM, Hackbarth DA, Wooldridge A, Mannem R, Bedi M.) Radiat Oncol. 2023 Mar 01;18(1):42 PMID: 36859309 PMCID: PMC9976442 SCOPUS ID: 2-s2.0-85149210071 03/02/2023
Abrupt onset of severe parkinsonism in a patient with metastatic gastrointestinal stromal tumor receiving treatment with avapritinib: A case report.

(Drom C, Schenheit K, Matzke M, Obeidat AZ, Molinaro J, Charlson J, Knight JM.) Brain Behav Immun Health. 2023 Feb;27:100570 PMID: 36578920 PMCID: PMC9791578 12/30/2022
Abrupt onset of severe parkinsonism in a patient with metastatic gastrointestinal stromal tumor receiving treatment with avapritinib: A case report

(Drom C, Schenheit K, Matzke M, Obeidat AZ, Molinaro J, Charlson J, Knight JM.) Brain, Behavior, and Immunity - Health. February 2023;27 SCOPUS ID: 2-s2.0-85144087911 02/01/2023
Leveraging Social Determinants of Health to Reduce Hospital Length of Stay: A Pilot QI Project for Solid Tumor Oncology Patients During the COVID-19 Pandemic.

(Kamaraju T, Atkinson D, Wright T, Charlosn J, Wetzel T, Campbell G, Cadman J, Williams J, Egede L, Retseck J, Banerjee A, Ehrlich V, Stolley M, Power S.) WMJ. 2022 Oct;121(3):205-211 PMID: 36301647 SCOPUS ID: 2-s2.0-85140859344 10/28/2022
Androgen receptor expression in patients with triple negative breast cancer treated with neoadjuvant chemotherapy: a single institution study.

(Sridhar N, Glisch C, Jawa Z, Chaudhary LN, Kamaraju S, Burfeind J, Charlson J, Chitambar CR, Jorns JM, Cheng YC.) J Cancer. 2022;13(8):2472-2476 PMID: 35711833 PMCID: PMC9174868 SCOPUS ID: 2-s2.0-85130459904 06/18/2022